Phase 4
Completed N=84
Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery
Kidney Transplant; Complications · Postoperative Residual Curarization · Postoperative Residual Weakness
Source: ClinicalTrials.gov NCT03923556 ↗
Enrolled (actual)
84
Serious AEs
9.5%
Results posted
May 2025
Primary outcomePrimary: Number of Patients With Hypoventilation in Post-anesthesia Care Unit (PACU) — 22; 23 Participants
◆ Published Evidence
Not yet cited
0citations
Postoperative residual neuromuscular blockade and hypoventilation after rocuronium and sugammadex or neostigmine for kidney transplantation: A randomized clinical trial.
Summary
The purpose of this study is to compare two medications that reverse muscle paralysis at the end of kidney transplant surgery with the goal of reducing residual muscle weakness and insufficient respiratory function after surgery.
Linked Publications
-
Postoperative residual neuromuscular blockade and hypoventilation after rocuronium and sugammadex or neostigmine for kidney transplantation: A randomized clinical trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Patients With Hypoventilation in Post-anesthesia Care Unit (PACU) |
22; 23 | — |
| SECONDARY Number of Patients With Presence of qTOF <0.9 in PACU |
13; 25 | — |
| SECONDARY Number of Participants With Kidney Graft Dysfunction |
2; 4 | — |
| SECONDARY Rate of Adverse Events Related to NMBR Medications |
0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- At least 18 years or older
- Diagnosed with severe kidney dysfunction (defined by plasma creatinine clearance 40 kg/m2
- Pre-existing oxygen or ventilatory dependency (24h use of oxygen or other noninvasive or invasive ventilatory support)
- Patients with any pulmonary, neuromuscular or other disease that severely limits their respiratory functional status (e.g. unable to achieve 4 Metabolic Equivalent of Tasks, METs, such as climbing up 1 flight of stairs)
- Presence of any contraindication for any of the study-related medications or interventions.
Data sourced from ClinicalTrials.gov (NCT03923556) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.